Of 185 patients , 126 randomized to endovascular therapy ( 87.6 % recanalized , 41.3 % 90-day mRS 0-2 ) and 59 to intravenous tissue-type plasminogen activator only ( 60.5 % recanalized , 30.5 % 90-day mRS 0-2 ) .